Cortimo Clinical Trial
Contact
130 S. Ninth Street
Suite 2400
Philadelphia, PA 19107
The Cortimo™ Clinical Trial combines a brain computer interface (BCI) with an existing robotic orthotic brace for patients with stroke. The project, which enrolled a single patient, aims to develop a BCI system to help stroke patients restore impaired arm control and functionality by utilizing brain-derived signals to control a robotic device that fits over the weaker arm. Engineers interpret the signals from the brain via artificial intelligence algorithms in order to decode a patient’s intention to trigger specific motions of the arm and hand brace. This project involves a multidisciplinary team composed of neurologists, neurosurgeons, engineers, and physical and occupational therapists and other medical professionals.
The overall device comprises two Multiports, each with two 8 × 8 microelectrode arrays, patient cables linked to external amplifiers, a decoding computer and a wearable, powered arm orthosis.
The scientific rationale for the trial is that following stroke, certain areas of the brain may continue to generate movement plans and that these instructions cannot activate actual movement because the stroke has either disrupted the original output pathways or has caused abnormal muscle-control responses. The participant will undergo pre-operative functional neuroimaging studies to identify which areas of the brain continue to activate with imagined movement in the paretic limb. Functional neuroimaging will help generate brain maps to guide the surgical team on the optimal locations of the cerebral cortex to implant the multiport sensor arrays. The idea is that by recording neural activity directly from the areas around the stroke that retain movement planning information, the overall Cortimo system can deploy that activity to restore the person’s ability to control the hand and use it for functional activities. The trial will also allow us to explore whether it is possible to retrain the nervous system to increase residual activity in any latent pathways that could not be perceived and enhanced in any other way.
Please see published article in Communications Medicine: